View More Recent Stories

Jul 3, 2018 04:15PM Baxter to Host Second Quarter 2018 Financial Results Conference Call for Investors
Jun 28, 2018 09:15AM Baxter Releases 2017 Corporate Responsibility Report and Reinforces Its Commitment to Enriching Communities Around the World
May 30, 2018 05:00PM Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress That Further Demonstrate Value of HDx Therapy Enabled by THERANOVA
May 30, 2018 06:30AM Baxter Unveiled Updates to SHARESOURCE Remote Patient Management Platform for Home Dialysis Patients at ERA-EDTA 2018
May 21, 2018 08:00AM Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference
Jul 25, 2016 02:40PM Trading Radar for 7/26: Apple (AAPL), McDonald's (MCD), 3M (MMM), Caterpillar (CAT), Verizon (VZ), [Conference Call] Under Armour (UA) Report
Apr 25, 2016 03:29PM Trading Radar for 4/26: Apple (AAPL), Chipotle (CMG), Twitter (TWTR), 3M ((MMM), Procter & Gamble (PG), Freeport-McMoRan (FCX) Report
Oct 26, 2015 02:16PM Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
Jun 25, 2015 07:00AM U.S. FDA Grants Priority Review for MM-398 New Drug Application
Jun 11, 2015 05:00PM Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
Jun 1, 2015 04:12PM Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
May 4, 2015 09:00AM Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 27, 2015 07:00AM Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Mar 27, 2014 05:21PM Market Wrap: Splitsville for Baxter; MS Office Now iPad Friendly; Third Q4 GDP Estimate Flat at 2.6%
Nov 18, 2013 10:45AM Notable Analyst Rating Changes 11/18: (LAMR) (BAX) (IKAN) Upgraded; (NVDA) (MSFT) (SVU) Downgraded
Baxter Announces U.S. FDA Clearance of Altapore Shape Bioactive Bone Graft for Use in Surgery
View More Recent Stories